# A Study of YL201 in Patients With Advanced Solid Tumors

> **NCT05434234** · PHASE1,PHASE2 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 312 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** YL201
- **DRUG:** YL201
- **DRUG:** YL201 and atezolizumab

## Key facts

- **NCT ID:** NCT05434234
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-25
- **Primary completion:** 2027-04-06
- **Final completion:** 2027-10-06
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434234, "A Study of YL201 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05434234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*